Choosing the Right Viral Vector for a Gene Therapy

<p>Gene therapy is promising to provide treatments and potential cures for a long list of rare, genetic diseases. A key element of these therapies are the viral vectors that are used to deliver and insert the genetic material used to treat a patient. Guangping Gao, co-director of the Li Weibo Institute for Rare Diseases Research, director of the Horae Gene Therapy Center and Viral Vector Core, and professor at the University of Massachusetts Medical School; and Phillip Tai, assistant professor at the University of Massachusetts Medical School, discuss a recent review article that they co-authored in Nature’s journal Signal Transduction and Targeted Therapy that looks at viral vector platforms for gene therapy. We spoke to the researchers about viral vectors, the role they play in gene therapy, and the decision process that goes into the selection of a vector of a specific gene therapy. <em>Thanks to </em><a href="https://www.pfizer.com/" rel="noopener noreferrer" target="_blank"><em>Pfizer, Inc</em></a><em>., </em><a href="https://www.bluebirdbio.com/" rel="noopener noreferrer" target="_blank"><em>Bluebird</em></a><em>, and </em><a href="https://www.novartis.com/our-company/novartis-pharmaceuticals/novartis-gene-therapies" rel="noopener noreferrer" target="_blank"><em>Novartis Gene Therapies</em></a><em> for their support of this podcast, part of our </em><a href="https://globalgenes.org/platforms-of-hope-advances-in-gene-therapy-and-gene-editing/" rel="noopener noreferrer" target="_blank"><em>Platforms of Hope: Advances in Gene Therapy and Gene Editing</em></a><em> series.</em></p>